Slaughter and May and Linklaters have secured key mandates advising on the latest blockbuster London IPO proposed for later in 2021. 

Biotech firm Oxford Nanopore, which specialises in the development of DNA sequencing technology, told investors in an announcement on Tuesday that it is preparing for a potential IPO on the London Stock Exchange in the second half of 2021.